BridgeBio's Acoramidis Shows Promise in Reducing Mortality and Hospitalization in ATTR-CM

BridgeBio Pharma has unveiled a promising post-hoc analysis at the Heart Failure Society of America Annual Scientific Meeting 2024, highlighting the potential of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The Phase 3 ATTRibute-CM study evaluated the drug's impact on all-cause mortality (ACM) and recurrent cardiovascular hospitalization (CVH) events. The results demonstrated a significant reduction in these events, showcasing acoramidis as a potential breakthrough treatment.

The analysis revealed a 42% reduction in the composite of ACM and recurrent CVH events at 30 months for patients treated with acoramidis compared to those on placebo. Furthermore, a 30.5% hazard reduction was observed using the Andersen-Gill model, underscoring the drug's efficacy in improving patient outcomes.

Jonathan Fox, M.D., Ph.D., Chief Medical Officer of BridgeBio Cardiorenal, emphasized the importance of data transparency and ongoing communication of trial results to assist healthcare providers in making informed decisions. The findings were presented by Daniel Judge, M.D., a cardiology expert, who noted that the stabilization of TTR with acoramidis could significantly enhance the quality of life for patients with ATTR-CM.

The promising results from the ATTRibute-CM trial suggest that acoramidis could become a first-line therapy for ATTR-CM, potentially transforming the treatment landscape for this condition.